Open-label, Single-Arm, Phase 2 Study of Oral HDAC-inhibitor Abexinostat in Patients With Relapsed or Refractory Follicular Lymphoma (FORERUNNER)
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 15 Jul 2019
Price : $35 *
At a glance
- Drugs Abexinostat (Primary)
- Indications Follicular lymphoma
- Focus Therapeutic Use
- Acronyms FORERUNNER
- Sponsors Xynomic Pharmaceuticals
- 09 Jul 2019 Planned primary completion date changed from 1 Sep 2019 to 1 Sep 2020.
- 09 Jul 2019 Status changed from recruiting to active, no longer recruiting.
- 29 Apr 2019 Planned number of patients changed from 51 to 139.